Last $0.07 USD
Change Today +0.0004 / 0.56%
Volume 4.2M
As of 8:10 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

advanced cell technology inc (ACTC) Snapshot

Open
$0.07
Previous Close
$0.07
Day High
$0.07
Day Low
$0.07
52 Week High
03/5/14 - $0.10
52 Week Low
06/13/14 - $0.05
Market Cap
240.2M
Average Volume 10 Days
6.9M
EPS TTM
$-0.02
Shares Outstanding
3.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVANCED CELL TECHNOLOGY INC (ACTC)

advanced cell technology inc (ACTC) Related Bloomberg News

View More Bloomberg News

advanced cell technology inc (ACTC) Related Businessweek News

No Related Businessweek News Found

advanced cell technology inc (ACTC) Details

Advanced Cell Technology, Inc., a biotechnology company, develops and commercializes human pluripotent stem cell technology in the field of regenerative medicine in the United States. The company is conducting various clinical trials for treating dry age-related macular degeneration and ocular therapies; and has a preclinical development pipeline focused on products for autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The company’s intellectual property portfolio also comprise cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs. As of March 27, 2014, it had 46 issued patents and 178 pending patent applications for the development of intellectual property portfolio. The company is headquartered in Marlborough, Massachusetts.

advanced cell technology inc (ACTC) Top Compensated Officers

Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $310.7K
Chief Scientific Officer
Total Annual Compensation: $586.2K
Compensation as of Fiscal Year 2013.

advanced cell technology inc (ACTC) Key Developments

Advanced Cell Technology Inc. Appoints Paul K. Wotton as Director

In connection with the previously announced appointment of Paul K. Wotton as Chief Executive Officer and President of Advanced Cell Technology Inc., the Board of Directors of the company appointed Dr. Wotton to serve as a director, effective July 31, 2014, until the next annual meeting of the company’s stockholders, where he will stand for election. The appointment of Dr. Wotton as a director brings the size of the company’s Board to six members.

Advanced Cell Technology Inc. - Special Call

To provide a corporate update

Advanced Cell Technology Inc. Appoints Paul K. Wotton as President and Chief Executive Officer

Advanced Cell Technology Inc. announced the appointment of Paul Wotton, Ph.D., to the position of President and Chief Executive Officer. Dr. Wotton joins ACT from Antares Pharma Inc. where he served as President and CEO since October, 2008.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTC:US $0.07 USD +0.0004

ACTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTC.
View Industry Companies
 

Industry Analysis

ACTC

Industry Average

Valuation ACTC Industry Range
No financial data is available for ACTC.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED CELL TECHNOLOGY INC, please visit www.advancedcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.